Genta Incorporated (GETA.OB) is a biopharmaceutical company focused on the identification, development and commercialization of drugs for the treatment of people with cancer.
Genta has three promising drugs in their pipeline: Tesetaxel, Genasense and Oral Gallium. Tesetaxel, a novel oral targeted tubulin inhibitor, was just granted Fast Track Designation by the FDA for Advanced Gastric Cancer. They also have a product in the market called Ganite (gallium nitrate injection), which is an important therapy used for serious cancer complications.
Genta has scheduled a conference call for May 13th before market open to discuss First Quarter 2010 Highlights.
They will also be presenting at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 4-9, 2010 in Chicago, IL.
Currently Genta’s stock price has bottomed at around .06 (which is a far cry from its 52 week high of $1.26.) According to Market Financial, Genta is “Poised For A Rebound Year Based On Latest Company Developments.” Genta’s stock will be volatile this week and could easily triple on good news from the Company. Genta is current, and always has been, with all SEC filings.
Disclosure: Writer receives no compensation from the company.
Genta’s Mission:
Innovation in Cancer Care Genta Incorporated is a biopharmaceutical company focused on the identification, development and commercialization of oncology drugs. Our strategy is to maximize shareholder value through excellence in performance and innovation, while maintaining the highest standards of integrity and leadership. Genta is committed to developing innovative products to better the lives of people with cancer.
